Emerging Pharmacotherapies for Diabetic Macular Edema

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Agent (# patients)</td><td align="left">Main Outcomes</td><td align="center">Reference</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Celecoxib (86)</td><td align="left">Unfavorable outcomes versus photocoagulation  at 2 years</td><td align="center">[<a href="/journals/jdr/2012/548732/#B80">81</a>]</td></tr><tr><td align="left">Nepafenac (1)</td><td align="left">Some evidence of efficacy in case report</td><td align="center">[<a href="/journals/jdr/2012/548732/#B82">83</a>]</td></tr><tr><td align="left">Etanercept (7)</td><td align="left">Some evidence of efficacy in pilot study</td><td align="center">[<a href="/journals/jdr/2012/548732/#B84">85</a>]</td></tr><tr><td align="left">Infliximab (4)</td><td align="left">Some evidence of efficacy in pilot study</td><td align="center">[<a href="/journals/jdr/2012/548732/#B86">87</a>]</td></tr><tr><td align="left">Mecamylamine (23)</td><td align="left">Some evidence of efficacy in pilot study</td><td align="center">[<a href="/journals/jdr/2012/548732/#B89">90</a>]</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Selected Other Ocular Agents in Treatment of Diabetic Macular Edema.

Journal of Diabetes Research

tab3

Table 3

Table 3: Emerging Pharmacotherapies for Diabetic Macular Edema 